Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Acasti Pharma Inc. is a biotechnology company focused on developing prescription drugs for the treatment of cardiovascular diseases, particularly through its lead product, CaPre, which is derived from krill oil. The company operates primarily in North America and is positioned to capitalize on the growing demand for omega-3 therapies, leveraging its unique formulation that enhances bioavailability.
Acasti Pharma generates revenue through the development and commercialization of its prescription drug, CaPre, targeting patients with hypertriglyceridemia. The company has a competitive advantage due to its proprietary formulation that aims to provide superior efficacy compared to traditional omega-3 products.
FDA approval status of CaPre
Clinical trial results and data releases
Partnerships or collaborations with larger pharmaceutical companies
Market adoption rates of CaPre post-launch
Regulatory changes affecting drug approval processes
Technological disruption in drug formulation or delivery methods
Emergence of alternative therapies for hypertriglyceridemia
Increased competition from established pharmaceutical companies
Liquidity risks due to negative cash flows and reliance on external funding
Potential for dilution if additional equity financing is required
low - The demand for pharmaceutical products is generally inelastic, but broader economic conditions can influence R&D funding and investment.
Minimal impact as Acasti is currently not reliant on debt financing, but higher rates could affect future capital raising efforts.
minimal
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has shown significant price volatility, reflecting the uncertain nature of biotech approvals and market acceptance.
